TASLY

Tip Ranks · Jul 14 at 07:08 AM

Tasly Delivers Profit Growth on Flat Revenue, Bolstering China Resources Pharmaceutical

Yicai · Mar 27 at 07:20 AM

Heart Drug Sales Soar in China After Education Guru Zhang Xuefeng Dies Suddenly

AASTOCKS · Mar 19 at 09:32 AM

CHINARES PHARMA subsidiary TASLY earned 1.105 billion RMB for the year, an increase of 15.6%

AASTOCKS · Feb 8 at 04:35 AM

China Resources Pharmaceutical's subsidiary TASLY earned 1.105 billion RMB last year, an increase of 15.7%

Wallstreetcn · Jan 27 at 04:41 AM

With only six months left until July 1, 2026, the implementation of Article 75 of the National Medical Products Administration's "Special Regulations on the Registration of Traditional Chinese Medicine" is entering its final window period. This regulation, referred to in the industry as the "death clause" for proprietary Chinese medicines, clearly states that after three years of implementation starting from July 1, 2023, the contraindications in the instructions will be prohibited

prnewswire · Jan 25 at 06:03 PM

19:00 ET Landmark FDA Move: First Quality Control Protocol for Mesenchymal Stromal Cells (MSCs) Sets New Therapeutic Standard